Thought Leadership
AI Is the New Baseline — Ignore It and Risk Being Flat-Footed
When observing the biotech landscape, it is clear that AI is poised to disrupt the industry — if it hasn't already — by driving meaningful productivity gains through everyday tools used across functions.
AI is the new Baseline -ignore it and risk being flat-footed! by Binesh Prabhakar
February 2026
"Leaders at small-to mid-size biotech organizations must start investing in AI now or risk being caught flat-footed!
In a previous post, I shared that AI should not be viewed merely as a tech enabler, but as a catalyst for meaningful innovation and improved clinical outcomes. That point is becoming increasingly evident in biotech.
When observing the biotech landscape, it is clear that AI is poised to disrupt the industry—if it hasn’t already—by driving meaningful productivity gains through everyday tools used across functions. Beyond operational efficiency, we are now witnessing substantial, strategic AI investments spanning discovery, clinical development, and commercial operations.
For example, while attending the 18th Annual Outsourcing in Clinical Trials West Coast (2026) in SFO, several recurring themes stood out:
Agentic AI platforms are accelerating protein discovery
GenAI and ML are applied to Clinical Study Reports (CSRs)
AI-driven chatbots are deployed for financial controls at clinical sites
AI-enabled tools are being leveraged for quality metrics and risk monitoring
The message is clear: ignoring AI, or offering lip service to it, is no longer sufficient.
Biotech leaders must invest in a pragmatic; achievable AI solutions aligned to business and clinical priorities. Those that delay risk falling behind organizations that are already embedding AI into their operating models and decision-making frameworks. AI is no longer optional. An AI Roadmap should be a start!
The question is not if biotech leaders should act—but how quickly and how thoughtfully they do so."